Serum Zinc and Copper Levels among Patients with Prostatic Cancer Attending National Cancer Institute, Gezira University, Sudan

Lina Mustafa khedir  Abdelmajid; Rawia Ibrahim Elameen  Hessen; Abuagla M.  Dafalla; Mutaz Ibrahim  Hassan; Yousif Abdelhameed  Mohammed

doi:10.52981/smlj.v10i2.2845

Lina Mustafa khedir Abdelmajid Clinical Chemistry Department, Faculty of Medical Laboratory Sciences, Gezira University, Sudan
Rawia Ibrahim Elameen Hessen Clinical Chemistry Department, Faculty of Medical Laboratory Sciences, Gezira University, Sudan
Abuagla M. Dafalla Clinical Chemistry Department, Faculty of Medical Laboratory Sciences, Gezira University, Sudan
Mutaz Ibrahim Hassan Clinical Chemistry Department, Faculty of Medical Laboratory Sciences, University of Shendi, Sudan
Yousif Abdelhameed Mohammed National Cancer Institute, Gezira University, Sudan

DOI: https://doi.org/10.52981/smlj.v10i2.2845

Keywords: Prostate cancer, Zinc, Copper, Risk factors, Sudanese

Abstract

Backgrounds: Prostate cancer is the most common cancer among Sudanese men and is equally distributed among its different tribes. Zinc (Zn) and copper (Cu) are one of the most important microelements and are ubiquitously present in the human body, and it is critical for maintaining prostate health and inhibiting prostate cancer development.

Objective: To assess serum zinc and copper levels among Sudanese prostatic cancer patients. Materials and Methods: A case-control study was carried out at National Cancer Institute from August 2020 to December 2020. The study included 60 Sudanese subjects, 30 of them were patients with prostate cancer and 30 were controls. The age of patients ranged between58-88. (43%) of patients were >70 Years and (57%) were <70 Years serum zinc and copper were measured by using atomic absorption spectrophotometer. Data were analysed using SPSS version (22).

Results: A highly significant decrease in zinc level in the case group (0.08±0.06) when compared with the control group (0.7±0.2) with p. value (p=0.000) and a highly significant increase in copper level in the case group (1.6±0.3) when compared with the control group (0.9±0.2) with p.value (p=0.000). There were no significant differences in Zn and copper levels according to age, BMI and duration with p. values (of 0.10, 0.70, 0.30), (0.28, 0.06, 0.52) respectively. Regarding Gleason stages patients with advanced stage,> score 7 (43%) (0.06±0.05) showed more decrease in zinc than patients with non-advanced stage ≤ score 7 (57%) (0.09±0.06) without significant differences (P=0.3) and showed more increase in copper than patients with non-advanced stage ≤ score 7 (57%) (1.47±0.50) without significant differences (P=0.37). There was a weak negative correlation between age, grade, stage and PSA with serum zinc with a coefficient r (-0.3, -0.03, -0.003, -0.2) respectively. While there was a weak positive correlation between BMI and duration with serum zinc with a coefficient r (0.07, 0.07) respectively. There was a moderate negative correlation between age, and duration with serum copper with a coefficient r (-0.20, -0.14). While serum copper had a moderate positive correlation with BMI, Stage, grade and PSA levels with a coefficient r (0.34, 0.28, 0.27, 0.27) respectively.

Conclusion: Serum zinc level in cases was lower than in controls; while serum copper level in cases was higher than in controls. The study recommended regular monitoring of serum zinc and copper in prostatic cancer patients.

References

1. Badal S, Aiken W, Morrison B, Valentine H, Bryan S, Gachii A, Ragin C. Disparities in prostate cancer incidence and mortality rates: Solvable or not?. The Prostate. 2020 Jan;80(1):3-16.
2. Drudge-Coates L, Turner B. Prostate cancer overview. Part 1: non-metastatic disease. British Journal of Nursing. 2012 May 9;21(Sup9):S23-8.
3. Junejo NN, AlKhateeb SS. BRCA2 gene mutation and prostate cancer risk: Comprehensive review and update. Saudi Medical Journal. 2020 Jan;41(1):9.
4. Saleh SA, Adly HM, Abdelkhaliq AA, Nassir AM. Serum levels of selenium, zinc, copper, manganese, and iron in prostate cancer patients. Current urology. 2020;14(1):44-9.
5. Mohamed AA, Abbas MY, Alharbi H, Babiker AY. Assessment of expression of Ki-67 in benign and malignant prostatic lesions among sudanese patients. Open Access Macedonian Journal of Medical Sciences. 2018 Oct 10;6 (10):1809.
6. Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, Sprenkle PC, Kattan MW, Colicchia M, Neville TB. Prostate-specific antigen trends predict the probability of prostate cancer in a very large US Veterans affairs cohort. Frontiers in oncology. 2018 Aug 6;8:296.
7. Gorish BM, Ournasseir ME, Shammat IM. Effect of Age, Geographical Affiliation and Environmental Factors on the Development of Prostate Cancer among Sudanese Patients. J Carcinog Mutagen. 2019;10(3):337.
8. Taha, S.M., Weng, H.Y., Mohammed, M.E.I., Osman, Y.M., N’dri, N.S., Mohammed, S.I. and Abuidris, D.O. Prostate cancer clinical characteristics and outcomes in Central Sudan. Cancer medical science, 2020:14.
9. Baudry J, Kopp JF, Boeing H, Kipp AP, Schwerdtle T, Schulze MB. Changes of trace element status during aging: results of the EPIC-Potsdam cohort study. European journal of nutrition. 2020 Oct;59(7):3045-58.
10. Hüssy K, Limburg KE, de Pontual H, Thomas OR, Cook PK, Heimbrand Y, Blass M, Sturrock AM. Trace element patterns in otoliths: the role of biomineralization. Reviews in Fisheries Science & Aquaculture. 2021 Oct 2;29(4):445-77.
11. Zaichick V, Zaichick S. Significance of trace element quantities in the prostatic secretion of patients with benign prostatic hyperplasia and prostate cancer. Journal of Cancer Metastasis and Treatment. 2019 Jun 13;5:48.
12. Eken A, Ünlü-Endirlik B, Kaya E, Özgök Y, Erdem O, Akay C. Evaluation of trace element levels in patients with prostate cancer, benign prostatic hyperplasia and chronic prostatitis. Gülhane Tip Dergisi. 2016 Mar 1;58(1):27.
13. Saleh SA, Adly HM, Abdelkhaliq AA, Nassir AM. Serum levels of selenium, zinc, copper, manganese, and iron in prostate cancer patients. Current urology. 2020;14(1):44-9.
14. Saleh SA, Adly HM, A Abdulkhaliq A, M Nassir A. Correlation of Some Trace Elements Serum Levels with Prostate Cancer Progression in Saudi Patients. The Open Public Health Journal. 2019 May 31;12(1).
15. Gholizadeh N, Pundavela J, Nagarajan R, Dona A, Quadrelli S, Biswas T, Greer PB, Ramadan S. Nuclear magnetic resonance spectroscopy of human body fluids and in vivo magnetic resonance spectroscopy: potential role in the diagnosis and management of prostate cancer. InUrologic Oncology: Seminars and Original Investigations 2020 Apr 1 (Vol. 38, No. 4, pp. 150-173). Elsevier.
16. Li D, Stovall DB, Wang W, Sui G. Advances of zinc signaling studies in prostate cancer. International Journal of Molecular Sciences. 2020 Jan 19;21(2):667.
17. Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, Rawla P, Barsouk A. Epidemiology, staging and management of prostate cancer. Medical Sciences. 2020 Jul 20;8(3):28.
18. Mayasula VK, Arunachalam A, Babatunde SA, Naidu SJ, Sellappana S, Krishnan BB, Rajendran US, Janardhan RI, Bhatta R. Trace minerals for improved performance: a review of Zn and Cu supplementation effects on male reproduction in goats. Tropical Animal Health and Production. 2021 Oct;53(5):1-8.
19. Singh CK, Chhabra G, Patel A, Chang H, Ahmad N. Dietary Phytochemicals in Zinc Homeostasis: A Strategy for Prostate Cancer Management. Nutrients. 2021 Jun;13(6):1867.
20. Kaba M, Pirincci N, Yuksel MB, Gecit I, Gunes M, Ozveren H, Eren H, Demir H. Serum levels of trace elements in patients with prostate cancer. Asian Pacific Journal of Cancer Prevention. 2014;15(6):2625-9.
21. Białkowska K, Marciniak W, Muszyńska M, Baszuk P, Gupta S, Jaworska-Bieniek K, Sukiennicki G, Durda K, Gromowski T, Prajzendanc K, Cybulski C. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS One. 2018 Jul 23;13(7):e0201065.
22. Mahmoud AM, Al-Alem U, Dabbous F, Ali MM, Batai K, Shah E, Kittles RA. Zinc intake and risk of prostate cancer: Case-control study and meta-analysis. PLoS One. 2016 Nov 8;11(11):e0165956.
23. Park SY, Wilkens LR, Morris JS, Henderson BE, Kolonel LN. Serum zinc and prostate cancer risk in a nested case–control study: the multiethnic cohort. The Prostate. 2013 Feb 15;73(3):261-6.